Vasopressin in the treatment of vasodilatory shock in children

Satoshi Masutani1, Hideaki Senzaki, Hirotaka Ishido

  • 1Department of Pediatric Cardiology and Cardiovascular Surgery, Saitama Heart Institute, Saitama Medical School Hospital, Saitama, Japan.

Insights

Vasopressin deficiency can cause catecholamine-resistant hypotension in children. Administering vasopressin (a hormone) effectively improved blood pressure and urinary output in pediatric patients with this condition.

Area of Science:

  • Pediatric critical care medicine
  • Endocrinology
  • Pharmacology

Background:

  • Vasopressin deficiency is a recognized cause of catecholamine-resistant hypotension in adults.
  • Limited data exists regarding vasopressin deficiency in pediatric patients.
  • Understanding this deficiency is crucial for managing pediatric shock.

Purpose of the Study:

  • To evaluate the efficacy of vasopressin administration in pediatric patients experiencing catecholamine-resistant hypotension.
  • To analyze the impact of vasopressin on urinary output and blood pressure in this population.

Main Methods:

  • Retrospective analysis of 12 pediatric patients (15 instances) treated with vasopressin for hypotension.
  • Causes of vasodilation included central nervous system disturbance, drug side-effects, and infection.
  • Plasma vasopressin levels were measured before and during vasopressin administration.

Main Results:

  • Patients were grouped based on response to vasopressin, with significant improvements in urinary output and/or blood pressure observed.
  • Low baseline plasma vasopressin concentrations were noted in hypotensive patients.
  • Vasopressin administration significantly increased plasma vasopressin levels.
  • No significant side-effects were reported.

Conclusions:

  • Vasopressin deficiency is a potential cause of catecholamine-resistant hypotension in children due to various underlying conditions.
  • Low-dose vasopressin administration appears effective in improving hemodynamic status and urinary output in pediatric patients.
  • Further research is warranted to establish optimal dosing and indications.
Abstract

Related Concept Videos

Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Blood Pressure Imbalances and Circulatory Shock01:24

Blood Pressure Imbalances and Circulatory Shock

Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...